Olympus Corporation
【Olympus】 Completion of Endoscope-Related Treatment Business Acquisition | May 2026
Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing the establishment of a wholly owned subsidiary. This aims to expand the endoscope-related business portfolio and strengthen cancer treatment solutions.
Key Figures
- Acquisition amount: approximately 43.3 billion yen
- Number of shares acquired: 16,925,621 shares
- BioProtect capital: 11,451 million yen
AI要約
Overview of the Acquisition
Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., establishing it as a wholly owned subsidiary. BioProtect develops implant technologies that protect healthy tissue during radiation therapy and surgical procedures, with its main product being a biodegradable balloon-type implant. This acquisition will expand the portfolio related to endoscope medical treatments and enhance solutions addressing unmet needs in cancer therapy. The acquisition amount is approximately 43.3 billion yen, with completion scheduled for June 1, 2026.
Future Outlook and Corporate Strategy
This acquisition is part of the management strategy announced in November 2025 and is a key measure in promoting innovation and simplifying business operations. It aims to improve care pathways starting from endoscopes and enhance patient outcomes, contributing to stronger solutions in cancer treatment. The specific impact on future performance is currently under assessment, and additional information will be promptly announced when available.
Olympus Corporation
Company overview · Stock price · Financial data · All IR
